US FDA Continues Reviewing Marketing Reports, Will It Punish Scofflaws?
Six months after submission deadline, about one-third of one-time marketing status reports have been reviewed, agency says.
You may also be interested in...
A firm will take ownership of US ANDAs from manufacturers unwilling to pay program fees or withdraw the approved generic drug application; is it a novel concept allowing future marketing options or simply fee avoidance?
Pre-ANDA meeting requests were high in some product categories where FDA conducted research projects, suggesting agency may influence sponsors' development priorities.